Regulation of apoptosis by PML and the PML-NBs

Oncogene

Volumn 27, Issue 48, 2008, Pages 6299-6312

  Bernardi, R ^a,b   Papa, A ^a   Pandolfi, P P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b San Raf faele Institute   (Italy)

Author keywords

APL; Apoptosis; Cancer; PML nuclear bodies; Tumor suppression

Indexed keywords

CASPASE 2; DAXX PROTEIN; DEATH RECEPTOR; FAS LIGAND; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN C JUN; PROTEIN P53;

APOPTOSIS; CANCER INHIBITION; CELL ACTIVITY; CELL FUNCTION; CELL MEMBRANE RESISTANCE; CELL NUCLEUS INCLUSION BODY; HUMAN; IN VIVO STUDY; MACROMOLECULE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; RECEPTOR UPREGULATION; REVIEW; STIMULUS RESPONSE;

ANIMALS; APOPTOSIS; CELL NUCLEUS; HUMANS; NUCLEAR PROTEINS; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 54249103056     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.305     Document Type: Review

References (104)

1. Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y. (2008). PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene 27: 3653-3661.
2. Bellodi C, Kindle K, Bernassola F, Cossarizza A, Dinsdale D, Melino G et al. (2006). A cytoplasmic PML mutant inhibits p53 function. Cell Cycle 5: 2688-2692.
3. Bernardi R, Pandolfi PP. (2003). Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22: 9048-9057.
4. Bernardi R, Pandolfi PP. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8: 1006-1016.
5. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. (2004). PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6: 665-672.
6. Best JL, Ganiatsas S, Agarwal S, Changou A, Salomoni P, Shirihai O et al. (2002). SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell 10: 843-855.
7. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. (2002). Deconstructing PML-induced premature senescence. EMBO J 21: 3358-3369.
8. Bissonnette N, Hunting DJ. (1998). p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16: 3461-3469.
9. Boisvert FM, Hendzel MJ, Bazett-Jones DP. (2000). Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol 148: 283-292.
10. Borden KL. (2002). Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol 22: 5259-5269.
11. Buschbeck M, Uribesalgo I, Ledl A, Gutierrez A, Minucci S, Muller S et al. (2006). PML4 induces differentiation by Myc destabilization. Oncogene 26: 3415-3422.
12. Cao X, Clavijo C, Li X, Lin HH, Chen Y, Shih HM et al. (2008). SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome. Mol Cancer Ther 7: 923-934.
13. Carbone R, Pearson M, Minucci S, Pelicci PG. (2002). PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21: 1633-1640.
14. Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH. (2007). Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13: 326-335.
15. Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. (1998). Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281: 1860-1863.
16. Chang KS, Fan YH, Andreeff M, Liu J, Mu ZM. (1995). The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 85: 3646-3653.
17. Cho Y, Lee I, Maul GG, Yu E. (1998). A novel nuclear substructure, ND10: distribution in normal and neoplastic human tissues. Int J Mol Med 1: 717-724.
18. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A et al. (2006). Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 66: 6192-6198.
19. Croxton R, Puto LA, de Belle I, Thomas M, Torii S, Hanaii F et al. (2006). Daxx represses expression of a subset of antiapoptotic genes regulated by nuclear factor-kappaB. Cancer Res 66: 9026-9035.
20. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. (2002). Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
21. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M et al. (1993). PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82: 1858-1867.
22. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G et al. (2004). PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13: 523-535.
23. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. (1991). The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675-684.
24. Dellaire G, Bazett-Jones DP. (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26: 963-977.
25. Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG et al. (2006). Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol 175: 55-66.
26. Emelyanov AV, Kovac CR, Sepulveda MA, Birshtein BK. (2002). The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells. J Biol Chem 277: 11156-11164.
27. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. (1997). A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J 16: 1519-1530.
28. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. (2000). PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027.
29. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K et al. (2000). Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195.
30. Fu C, Ahmed K, Ding H, Ding X, Lan J, Yang Z et al. (2005). Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24: 5401-5413.
31. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W et al. (2000). The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
32. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. (2002). Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277: 13430-13437.
33. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al. (2004a). Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96: 269-279.
34. Gurrieri C, Nafa K, Merghoub T, Bernardi R, Capodieci P, Biondi A et al. (2004b). Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 103: 2358-2362.
35. Halazonetis TD, Gorgoulis VG, Bartek J. (2008). An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355.
36. Hayakawa F, Privalsky ML. (2004). Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5: 389-401.
37. Hayashi N, Shirakura H, Uehara T, Nomura Y. (2006). Relationship between SUMO-1 modification of caspase-7 and its nuclear localization in human neuronal cells. Neurosci Lett 397: 5-9.
38. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W et al. (2002). Regulation of p53 activity by its interaction with homeo-domain- interacting protein kinase-2. Nat Cell Biol 4: 1-10.
39. Hofmann TG, Will H. (2003). Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 10: 1290-1299.
40. Imai Y, Kimura T, Murakami A, Yajima N, Sakamaki K, Yonehara S. (1999). The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature 398: 777-785.
41. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221-234.
42. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et al. (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453: 1072-1078.
43. Jensen K, Shiels C, Freemont PS. (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233.
44. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV et al. (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674.
45. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. (2000). Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620.
46. Komura N, Asakawa M, Umezawa K, Segawa K. (2007). Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells. Exp Cell Res 313: 2753-2765.
47. Krieghoff E, Milovic-Holm K, Hofmann TG. (2007). FLASH meets nuclear bodies: CD95 receptor signals via a nuclear pathway. Cell Cycle 6: 771-775.
48. Kurki S, Latonen L, Laiho M. (2003). Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci 116: 3917-3925.
49. Lackinger D, Kaina B. (2000). Primary mouse fibroblasts deficient for c-Fos, p53 or for both proteins are hypersensitive to UV light and alkylating agent-induced chromosomal breakage and apoptosis. Mutat Res 457: 113-123.
50. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. (2008). Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555.
51. Lassus P, Opitz-Araya X, Lazebnik Y. (2002). Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297: 1352-1354.
52. Le XF, Vallian S, Mu ZM, Hung MC, Chang KS. (1998). Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene 16: 1839-1849.
53. Lehembre F, Muller S, Pandolfi PP, Dejean A. (2001). Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene 20: 1-9.
54. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ et al. (2000). Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol 20: 1784-1796.
55. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J et al. (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653.
56. Lin HK, Bergmann S, Pandolfi PP. (2004). Cytoplasmic PML function in TGF-beta signalling. Nature 431: 205-211.
57. Liu JH, Mu ZM, Chang KS. (1995). PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J Exp Med 181: 1965-1973.
58. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y. (2003). The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 278: 33134-33141.
59. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P. (2008). A role for cytoplasmic PML in cellular resistance to viral infection. PLoS ONE 3: e2277.
60. Meinecke I, Cinski A, Baier A, Peters MA, Dankbar B, Wille A et al. (2007). Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci USA 104: 5073-5078.
61. Melnick A, Licht JD. (1999). Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215.
62. Michaelson JS, Bader D, Kuo F, Kozak C, Leder P. (1999). Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev 13: 1918-1923.
63. Michaelson JS, Leder P. (2003). RNAi reveals anti-apoptotic and transcriptionally repressive activities of DAXX. J Cell Sci 116: 345-352.
64. Milovic-Holm K, Krieghoff E, Jensen K, Will H, Hofmann TG. (2007). FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. EMBO J 26: 391-401.
65. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Droge W et al. (2003). PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63: 4310-4314.
66. Morgan M, Thorburn J, Pandolfi PP, Thorburn A. (2002). Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via differentmechanism s. J Cell Biol 157: 975-984.
67. Mu ZM, Le XF, Vallian S, Glassman AB, Chang KS. (1997). Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis 18: 2063-2069.
68. Mukhopadhyay D, Ayaydin F, Kolli N, Tan SH, Anan T, Kametaka A et al. (2006). SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J Cell Biol 174: 939-949.
69. Nguyen LA, Pandolfi PP, Aikawa Y, Tagata Y, Ohki M, Kitabayashi I. (2005). Physical and functional link of the leukemia-associated factors AML1 and PML. Blood 105: 292-300.
70. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F et al. (1991). Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6: 1285-1292.
71. Paroni G, Henderson C, Schneider C, Brancolini C. (2002). Caspase-2 can trigger cytochrome C release and apoptosis from the nucleus. J Biol Chem 277: 15147-15161.
72. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210.
73. Petrie K, Zelent A. (2008). Marked for death. Nat Cell Biol 10: 507-509.
74. Piazza F, Gurrieri C, Pandolfi PP. (2001). The theory of APL. Oncogene 20: 7216-7222.
75. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. (1998). PML induces a novel caspase-independent death process. Nat Genet 20: 259-265.
76. Reineke EL, Lam M, Liu Q, Liu Y, Stanya KJ, Chang KS et al. (2008). Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol 28: 997-1006.
77. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. (2005). The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 105: 3686-3690.
78. Sanchez-Pulido L, Valencia A, Rojas AM. (2007). Are promyelocytic leukaemia protein nuclear bodies a scaffold for caspase-2 programmed cell death? Trends Biochem Sci 32: 400-406.
79. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B et al. (2006). A CK2-dependentme chanism for degradation of the PML tumor suppressor. Cell 126: 269-283.
80. Seeler JS, Dejean A. (2003). Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4: 690-699.
81. Seker H, Rubbi C, Linke SP, Bowman ED, Garfield S, Hansen L et al. (2003). UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene 22: 1620-1628.
82. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. (2006). The mechanisms of PML-nuclear body formation. Mol Cell 24: 331-339.
83. Smith ML, Fornace Jr AJ. (1997). p53-mediated protective responses to UV irradiation. Proc Natl Acad Sci USA 94: 12255-12257.
84. Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, Saib A et al. (1995). Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11: 2565-2573.
85. Tagata Y, Yoshida H, Nguyen LA, Kato H, Ichikawa H, Tashiro F et al. (2008). Phosphorylation of PML is essential for activation of C/EBP epsilon and PU.1 to accelerate granulocytic differentiation. Leukemia 22: 273-280.
86. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. (2004). PML nuclear bodies and apoptosis. Oncogene 23: 2819-2824.
87. Tan JA, Sun Y, Song J, Chen Y, Krontiris TG, Durrin LK. (2008). Sumo conjugation to the MAR-binding protein, special at-rich sequence binding protein-1, targets it to promyelocytic nuclear bodies where it undergoes caspase cleavage. J Biol Chem 283: 18124-18134.
88. Tang J, Xie W, Yang X. (2005). Association of caspase-2 with the promyelocytic leukemia protein nuclear bodies. Cancer Biol Ther 4: 645-649.
89. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 538-546.
90. Torii S, Egan DA, Evans RA, Reed JC. (1999). Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J 18: 6037-6049.
91. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874.
92. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. (2006). Identification of a tumour suppressor network opposing nuclear Aktfun ction. Nature 441: 523-527.
93. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. (1996). Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716.
94. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al. (1998). PML is essential for multiple apoptotic pathways. Nat Genet 20: 266-272.
95. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB et al. (2003). Physical and functional interactions between PML and MDM2. J Biol Chem 278: 29288-29297.
96. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, Chang KS. (2003). Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem 278: 12294-12304.
97. Yang S, Jeong JH, Brown AL, Lee CH, Pandolfi PP, Chung JH et al. (2006). Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem 281: 26645-26654.
98. Yang S, Kuo C, Bisi JE, Kim MK. (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/ Chk2. Nat Cell Biol 4: 865-870.
99. Yang X, Khosravi-Far R, Chang HY, Baltimore D. (1997). Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89: 1067-1076.
100. Yoshida H, Ichikawa H, Tagata Y, Katsumoto T, Ohnishi K, Akao Y et al. (2007). PML-RARA inhibits PML IV enhancement of PU.1-induced C/EBP{epsilon} expression in myeloid differentiation. Mol Cell Biol 27: 273-280.
101. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. (2000a). Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748-2752.
102. Zhong S, Salomoni P, Pandolfi PP. (2000b). The transcriptional role of PML and the nuclear body. Nat Cell Biol 2: E85-E90.
103. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP. (2000c). Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 191: 631-640.
104. Zhu H, Wu L, Maki CG. (2003). MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem 278: 49286-49292.